Lord, Abbett & Co. LLC Xencor Inc Transaction History

Lord, Abbett & Co. LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$33.73 - $46.27 $7.36 Million - $10.1 Million	-218,074 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$29.6 - $40.93 $837,413 - $1.16 Million	28,291 Added 14.91%	218,074 $8.93 Million
Q1 2019 May 15, 2019	SELL	$27.85 - $38.09 $119,727 - $163,748	-4,299 Reduced 2.22%	189,783 $5.9 Million
Q4 2018 Feb 14, 2019	BUY	$32.39 - $42.05 $109,575 - $142,255	3,383 Added 1.77%	194,082 $7.02 Million
Q3 2018 Nov 14, 2018	BUY	$35.69 - $47.65 $551,017 - $735,668	15,439 Added 8.81%	190,699 $7.43 Million
Q2 2018 Aug 14, 2018	SELL	$28.41 - $42.41 $94,917 - $141,691	-3,341 Reduced 1.87%	175,260 $6.49 Million
Q1 2018 May 15, 2018	SELL	$21.18 - $33.78 $1.57 Million - $2.5 Million	-74,010 Reduced 29.3%	178,601 $5.35 Million
Q4 2017 Feb 14, 2018	SELL	$19.29 - $24.83 $114,119 - $146,894	-5,916 Reduced 2.29%	252,611 $5.54 Million
Q3 2017 Nov 14, 2017	SELL	$19.61 - $23.35 $1.86 Million - $2.22 Million	-94,971 Reduced 26.87%	258,527 $5.93 Million
Q2 2017 Aug 14, 2017	BUY	N/A	353,498	353,498 $7.46 Million

215

71.5M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.44B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.